a
<We_can_help/>

What are you looking for?

>Shirley Liu
speaker_info

About The Speaker

Shirley Liu

GV20 THERAPEUTICS, CO-FOUNDER & CEO

Shirley Liu

GV20 THERAPEUTICS, CO-FOUNDER & CEO

Dr. Xiaole Shirley Liu co-founded GV20 Therapeutics in 2016 and became the CEO of GV20 in 2022. She was a Professor of Biostatistics and Computational Biology at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health and co-director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her computational biology work refined our understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors in different cancers.

Dr. Liu is a highly cited researcher with a prodigious publication record that includes more than 200 papers published by her group, many in high-profile journals and highly cited. Shirley received the Sloan Research Fellowship (2008), has been a Breast Cancer Research Foundation Investigator (2017) and became a Fellow of ISCB (2019). In addition, she was recognized with the Benjamin Franklin Award for Open Access in the Life Sciences and the ISCB Innovator Award in 2020.

Recently, she was selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.

The Antibody Series
Register now for free upcoming on-demand access to talks